What's the deal with that new Alzheimer's drug?

Matt and Dara are joined by Vox's Dylan Scott to learn about aducanumab, the new drug that was recently approved by the FDA for treating Alzheimer's disease despite a lack of evidence of its effectiveness, possibly serious side effects, and a jaw-droppingly high price tag. Matt, Dara, and Dylan discuss the situation in light of lessons learned, or not quite learned, from the global pandemic. Then, some research is discussed that evaluates the effects of work requirements on supplemental nutrition assistance program (SNAP) participation and the workforce.

Resources:

"The new Alzheimer's drug that could break Medicare" by Dylan Scott (June 10; Vox)

"FDA's Decision to Approve New Treatment for Alzheimer's Disease" by Dr. Patrizia Cavazzoni, Director, FDA Center for Drug Evaluation and Research (June 7)

"The maddening saga of how an Alzheimer's 'cabal' thwarted progress toward a cure for decades" by Sharon Begley (June 25, 2019; STAT News)

"What the Rich Don't Want to Admit About the Poor" by Ezra Klein (June 13; New York Times)

White paper: "Employed in a SNAP? The Impact of Work Requirements on Program Participation and Labor Supply" by Colin Grey, et al. (Sept. 2019)

Hosts:

Matt Yglesias (@mattyglesias), Slowboring.com

Dara Lind (@DLind), Immigration Reporter, ProPublica

Dylan Scott (@dylanlscott), Policy Reporter, Vox

Credits:

Erikk Geannikis, Editor and Producer

As the Biden administration gears up, we'll help you understand this unprecedented burst of policymaking. Sign up for The Weeds newsletter each Friday: vox.com/weeds-newsletter.

The Weeds is a Vox Media Podcast Network production.

Want to support The Weeds? Please consider making a contribution to Vox: bit.ly/givepodcasts

About Vox

Vox is a news network that helps you cut through the noise and understand what's really driving the events in the headlines.

Follow Us: Vox.com

Facebook group: The Weeds

Learn more about your ad choices. Visit podcastchoices.com/adchoices